Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 3
2010 6
2011 3
2012 7
2013 4
2014 9
2015 10
2016 8
2017 8
2018 10
2019 8
2020 13
2021 19
2022 10
2023 11
2024 8
2025 14
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Results by year

Citations

4 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Hyperkalemia treatment standard.
Palmer BF, Clegg DJ. Palmer BF, et al. Nephrol Dial Transplant. 2024 Jun 28;39(7):1097-1104. doi: 10.1093/ndt/gfae056. Nephrol Dial Transplant. 2024. PMID: 38425037 Free article. Review.
Nevertheless, the disorder is not benign since chronic hyperkalemia is associated with increased morbidity and mortality. The approach to patients with chronic hyperkalemia begins with a review of medications potentially responsible for the disorder, e …
Nevertheless, the disorder is not benign since chronic hyperkalemia is associated with increased morbidity and mortality. The …
Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis.
Huang N, Xu Y, Liu C, Liu Y, Fan Y, Li Z, Zhang D, Mao H, Chen W. Huang N, et al. Drugs. 2025 Aug;85(8):1013-1031. doi: 10.1007/s40265-025-02198-6. Epub 2025 Jun 21. Drugs. 2025. PMID: 40542996 Free PMC article.
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASi) and its combination therapy are essential supportive treatments for patients with chronic kidney disease (CKD) and heart failure (HF). ...The highest incidence of HK was observed with …
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASi) and its combination therapy are essential supportive treatments f …
SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors.
Wing S, Ray JG, Yau K, Jeyakumar N, Abdullah S, Luo B, Cherney DZI, Harel Z, Hundemer GL, Mavrakanas TA, Molnar AO, Odutayo A, Perl J, Young A, Charytan D, Weir M, Wald R. Wing S, et al. JAMA Intern Med. 2025 Jul 1;185(7):827-836. doi: 10.1001/jamainternmed.2025.0686. JAMA Intern Med. 2025. PMID: 40293730 Free PMC article.
OBJECTIVE: To evaluate the association between SGLT2i initiation and hyperkalemia in individuals receiving RAASi with a background of diabetes, heart failure, or chronic kidney disease. ...In the overall cohort, 95% had diabetes, 17% had heart failure, …
OBJECTIVE: To evaluate the association between SGLT2i initiation and hyperkalemia in individuals receiving RAASi with a background of …
Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors.
Fravel MA, Meaney CJ, Noureddine L. Fravel MA, et al. Curr Hypertens Rep. 2023 Nov;25(11):395-404. doi: 10.1007/s11906-023-01265-1. Epub 2023 Sep 25. Curr Hypertens Rep. 2023. PMID: 37747576 Review.
PURPOSE OF REVIEW: Use of renin-angiotensin-aldosterone system (RAAS) inhibiting medications is critical in the prevention of cardiovascular disease and kidney function decline in patients with chronic kidney disease (CKD); however, these …
PURPOSE OF REVIEW: Use of renin-angiotensin-aldosterone system (RAAS) inhibiting medications is critical in the prevention of cardiov …
New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.
Rastogi A, Arman F, Alipourfetrati S. Rastogi A, et al. Curr Hypertens Rep. 2016 Jul;18(7):55. doi: 10.1007/s11906-016-0663-4. Curr Hypertens Rep. 2016. PMID: 27230070 Review.
Hyperkalemia, a potentially life-threatening side effect of RAAS inhibitors, limits their use. The recent introduction of new hyperkalemia treatments provides opportunities to take full benefit of RAAS inhibitors. RECENT FINDINGS: Optimiz …
Hyperkalemia, a potentially life-threatening side effect of RAAS inhibitors, limits their use. The recent introduction …
Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management.
Beavers CJ, Greene SJ. Beavers CJ, et al. Heart Fail Rev. 2025 Dec;30(6):1291-1305. doi: 10.1007/s10741-025-10549-4. Epub 2025 Aug 22. Heart Fail Rev. 2025. PMID: 40841869 Free PMC article. Review.
The prevalence of hyperkalemia in HF patients is notably higher compared to the general population, particularly in those with comorbid chronic kidney disease (CKD) and diabetes mellitus, further complicating management. This review emphasizes the impo …
The prevalence of hyperkalemia in HF patients is notably higher compared to the general population, particularly in those with comorb …
Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors.
Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Epstein M, et al. Am J Manag Care. 2015 Sep;21(11 Suppl):S212-20. Am J Manag Care. 2015. PMID: 26619183 Free article.
STUDY DESIGN: De-identified medical records from a large database of electronic health records (Humedica) for patients 5 years of age or older with at least 2 serum potassium readings were analyzed (N = 205,108 patients; 1.7 million records). METHODS: Inclusion criteria required …
STUDY DESIGN: De-identified medical records from a large database of electronic health records (Humedica) for patients 5 years of age or old …
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.
Riccio E, Capuano I, Buonanno P, Andreucci M, Provenzano M, Amicone M, Rizzo M, Pisani A. Riccio E, et al. Front Cardiovasc Med. 2022 Feb 11;9:824095. doi: 10.3389/fcvm.2022.824095. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35224054 Free PMC article.
Hyperkalemia is common in patients treated with renin-angiotensin-aldosterone system inhibitors (RAASis), and it represents the main cause of the large gap reported between guideline recommendations and real-world practice in chronic kidney disease …
Hyperkalemia is common in patients treated with renin-angiotensin-aldosterone system inhibitors (RAASis), and it represents th …
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies.
Valdivielso JM, Balafa O, Ekart R, Ferro CJ, Mallamaci F, Mark PB, Rossignol P, Sarafidis P, Del Vecchio L, Ortiz A. Valdivielso JM, et al. Drugs. 2021 Sep;81(13):1467-1489. doi: 10.1007/s40265-021-01555-5. Epub 2021 Jul 27. Drugs. 2021. PMID: 34313978 Free article. Review.
Despite recent therapeutic advances, chronic kidney disease (CKD) is one of the fastest growing global causes of death. This illustrates limitations of current therapeutic approaches and, potentially, unidentified knowledge gaps. ...Indeed, hyperkalemia …
Despite recent therapeutic advances, chronic kidney disease (CKD) is one of the fastest growing global causes of death. …
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators. Weir MR, et al. N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21. N Engl J Med. 2015. PMID: 25415805 Free article. Clinical Trial.
We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to …
We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients wit …
138 results